Summary: TG Therapeutics, Inc. reported a modest Q3 beat and raised the full-year net sales
Summary: TG Therapeutics’ Q3 earnings missed EPS expectations, primarily due to higher non-cash compensation and
TG Therapeutics (NASDAQ:TGTX) has signed a multi-year manufacturing supply agreement with FUJIFILM Diosynth Biotechnologies (OTCPK:FUJIY)
TG Therapeutics press release (NASDAQ:TGTX): Q3 GAAP EPS of $0.02 misses by $0.01. Revenue of
Summary: Shares of TG Therapeutics made new 52-week highs this week, helped in part by
Summary: TG Therapeutics’ Briumvi shows strong revenue growth, with Q2 2024 revenue up 350% YoY,
Summary: TG Therapeutics exceeded Q2 Street consensus estimates, with Briumvi net sales of $72.6 million
Blue Owl Capital (NYSE:OWL) and HealthCare Royalty have entered into a $250M term loan facility
filo TG Therapeutics (NASDAQ:TGTX) shares rose ~16% in the premarket on Wednesday after the biotech
TG Therapeutics press release (NASDAQ:TGTX): Q2 GAAP EPS of $0.04 beats by $0.09. Revenue of